Literature DB >> 10519723

Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A.

E Mercuri1, J Poulton, J Buck, V Broadbent, M Bamford, H Jungbluth, A Y Manzur, F Muntoni.   

Abstract

A 5 year old boy developed severe weakness after receiving vincristine for treatment of acute lymphoblastic leukaemia. Although weakness improved after the discontinuation of vincristine, other symptoms suggestive of a neuropathy persisted. Neurophysiological and genetic analysis at age 8 years indicated that vincristine had induced symptoms of a hereditary sensory motor neuropathy type 1A, which had previously been asymptomatic; his genetically affected mother was also asymptomatic.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10519723      PMCID： PMC1718125          DOI： 10.1136/adc.81.5.442

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  6 in total

1.  [Charcot-Marie-Tooth disease disclosed by a treatment with vincristine in familial Hodgkin's disease].

Authors:  C Geny; J M Gaio; M Mallaret; A Goy; F Reymond; B Pegourie; J Yulis; J E Perret
Journal:  Ann Med Interne (Paris)       Date:  1990

2.  Vincristine neuropathy. Clinical and electrophysiological observations.

Authors:  E B Casey; A M Jellife; P M Le Quesne; Y L Millett
Journal:  Brain       Date:  1973       Impact factor: 13.501

3.  Vincristine neuropathy in type I and type II Charcot-Marie-Tooth disease (hereditary motor sensory neuropathy).

Authors:  M Igarashi; E I Thompson; G K Rivera
Journal:  Med Pediatr Oncol       Date:  1995-08

4.  Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A.

Authors:  W D Graf; P F Chance; M W Lensch; L J Eng; H P Lipe; T D Bird
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

5.  Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease.

Authors:  Y Neumann; A Toren; G Rechavi; B Seifried; N G Shoham; M Mandel; G Kenet; N Sharon; M Sadeh; R Navon
Journal:  Med Pediatr Oncol       Date:  1996-04

Review 6.  Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I.

Authors:  S A McGuire; S M Gospe; G Dahl
Journal:  Med Pediatr Oncol       Date:  1989
  6 in total
  6 in total

1.  Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation.

Authors:  Tomonori Nakamura; Akihiro Hashiguchi; Shinsuke Suzuki; Kimiharu Uozumi; Shoko Tokunaga; Hiroshi Takashima
Journal:  Neurogenetics       Date:  2012-01-25       Impact factor: 2.660

Review 2.  Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health.

Authors:  Kirsten K Ness; Saro H Armenian; Nina Kadan-Lottick; James G Gurney
Journal:  Expert Rev Hematol       Date:  2011-04       Impact factor: 2.929

3.  Vincristine-induced neuropathy in rat: electrophysiological and histological study.

Authors:  Feras M H Ja'afer; Farqad B Hamdan; Faiq H Mohammed
Journal:  Exp Brain Res       Date:  2006-05-31       Impact factor: 1.972

4.  Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1).

Authors:  Patrick P Hess; Monica S Ventura Ferreira; Benjamin Rolles; Martin Kirschner; Florian Holtbernd; Mareike Tometten; Tim H Brümmendorf; Fabian Beier
Journal:  Clin Case Rep       Date:  2022-05-05

5.  Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy.

Authors:  Andreas S Beutler; Amit A Kulkarni; Rahul Kanwar; Christopher J Klein; Terry M Therneau; Rui Qin; Michaela S Banck; Ganesh K Boora; Kathryn J Ruddy; Yanhong Wu; Regenia L Smalley; Julie M Cunningham; Nguyet Anh Le-Lindqwister; Peter Beyerlein; Gary P Schroth; Anthony J Windebank; Stephan Züchner; Charles L Loprinzi
Journal:  Ann Neurol       Date:  2014-09-17       Impact factor: 10.422

6.  Effects of antiretroviral therapy in patients with Charot-Marie-Tooth disease type 1A.

Authors:  J L Fernández-Torre; M García-Alcalde; V Alvarez
Journal:  J Neurol       Date:  2002-07       Impact factor: 4.849
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.